

LY5

## Chemical Properties


CAS No. : 1436382-03-4

Formula: C<sub>15</sub>H<sub>11</sub>N<sub>3</sub>O<sub>4</sub>S

Molecular Weight: 329.33

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

|               |   |
|---------------|---|
| Description   | LY5 is an inhibitor of STAT3 that acts by inhibiting cell viability, cell migration, and angiogenesis in medulloblastoma cells. |
| Targets(IC50) | Apoptosis,Others,STAT   |

## Preparing Stock Solutions

|       | 1mg       | 5mg        | 10mg       |
|-------|-----------|------------|------------|
| 1 mM  | 3.0365 mL | 15.1823 mL | 30.3647 mL |
| 5 mM  | 0.6073 mL | 3.0365 mL  | 6.0729 mL  |
| 10 mM | 0.3036 mL | 1.5182 mL  | 3.0365 mL  |
| 50 mM | 0.0607 mL | 0.3036 mL  | 0.6073 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Qiao X, Rao P, Zhang Y, Liu L, Pang M, Wang H, Hu M, Tian X, Zhang J, Zhao Y, Wang XM, Wang C, Yu H, Guo F, Cao Q, Wang Y, Wang YM, Zhang GY, Lee VW, Alexander SI, Zheng G, Harris DCH. Redirecting TGF- $\beta$  Signaling through the  $\beta$ -Catenin/Foxo Complex Prevents Kidney Fibrosis. *J Am Soc Nephrol*. 2018 Feb;29(2):557-570. doi: 10.1681/ASN.2016121362. Epub 2017 Nov 27. PubMed PMID: 29180394; PubMed Central PMCID: PMC5791062.

Chiba Y, Mizoguchi I, Furusawa J, Hasegawa H, Ohashi M, Xu M, Owaki T, Yoshimoto T. Interleukin-27 Exerts Its Antitumor Effects by Promoting Differentiation of Hematopoietic Stem Cells to M1 Macrophages. *Cancer Res*. 2018 Jan 1;78(1):182-194. doi: 10.1158/0008-5472.CAN-17-0960. Epub 2017 Nov 1. PubMed PMID: 29093008.

Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. *PLoS One*. 2017 Jul 27;12(7):e0181885. doi: 10.1371/journal.pone.0181885. eCollection 2017. PubMed PMID: 28750090; PubMed Central PMCID: PMC5531494.

Wang Y, Huang D, Chen KY, Cui M, Wang W, Huang X, Awadallah A, Li Q, Friedman A, Xin WW, Di Martino L, Cominelli F, Miron A, Chan R, Fox JG, Xu Y, Shen X, Kalady MF, Markowitz S, Maillard I, Lowe JB, Xin W, Zhou L. Fucosylation Deficiency in Mice Leads to Colitis and Adenocarcinoma. *Gastroenterology*. 2017 Jan;152(1):193-205. e10. doi: 10.1053/j.gastro.2016.09.004. Epub 2016 Sep 14. PubMed PMID: 27639802; PubMed Central PMCID: PMC5164974.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481